{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:16:25Z","timestamp":1753892185507,"version":"3.41.2"},"reference-count":61,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T00:00:00Z","timestamp":1742515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Psoriasis vulgaris (PV) is an inflammatory, chronically relapsing dermatological disease associated with significant comorbidities. Ixekizumab is recommended as the first-line therapy for severe PV, but encounters persistent challenges with relapse after treatment discontinuation. In clinical practice, Chinese herbal medicine (CHM) including Guben Qushi Huayu formula (GQHF) has been demonstrated effective in reducing PV relapse. However, there remains a scarcity of high-level evidence-based study in this respect. Therefore, this study aims to preliminarily evaluate the feasibility and acceptability of Ixekizumab combined with GQHF in reducing PV relapse.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods and analysis<\/jats:title><jats:p>This study employs a mixed-method research (MMR) design, encompassing both quantitative and qualitative studies. The quantitative study consists of a randomized controlled trial involving 50 participants with severe PV, who will be randomly allocated to the intervention group (Ixekizumab plus GQHF) and the control group (Ixekizumab plus GQHF placebo) in a 1:1 ratio. Relapse rate is the primary endpoint. The qualitative study involves semi-structured interviews to concurrently explore the acceptability of the application of Ixekizumab combined with GQHF among the enrolled participants.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>This pilot study utilizes MMR to investigate the effect of Ixekizumab combined with GQHF in reducing PV relapse. The findings are expected to provide valuable clinical evidence and a novel therapeutic option for PV. Moreover, it is our intention to conduct a larger MMR trial to further strengthen the clinical evidence and broaden the application of Ixekizumab in combination with GQHF.<\/jats:p><\/jats:sec><jats:sec><jats:title>Clinical Trial Registration<\/jats:title><jats:p><jats:ext-link>https:\/\/www.chictr.org.cn\/index.html<\/jats:ext-link>, identifier ChiCTR2100054950.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1551001","type":"journal-article","created":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T05:16:55Z","timestamp":1742534215000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Chinese herbal medicine (Guben Qushi Huayu formula) combined with Ixekizumab in reducing psoriasis vulgaris relapse: Protocol for a mixed-methods research study"],"prefix":"10.3389","volume":"16","author":[{"given":"Ziqing","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kewen","family":"Guan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuyan","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingwen","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danni","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhong","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuanjian","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingjie","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1111\/jdv.15340","article-title":"French guidelines on the use of systemic treatments for moderate-to-severe psoriasis in adults","volume":"33","author":"Amatore","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1001\/jamadermatol.2021.2007","article-title":"Psoriasis Prevalence in adults in the United States","volume":"157","author":"Armstrong","year":"2021","journal-title":"JAMA Dermatol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical Presentation, and treatment of psoriasis: A review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e136","DOI":"10.1111\/bjd.15446","article-title":"Dermatology Life Quality Index (DLQI) as a psoriasis referral triage tool","volume":"177","author":"Atwan","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/S0140-6736(15)60857-1","article-title":"Interleukin-17 inhibition: a route to psoriasis clearance?","volume":"386","author":"Bachelez","year":"2015","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2546161","DOI":"10.1155\/2019\/2546161","article-title":"Short-term efficacy and safety of IL-17, IL-12\/23, and IL-23 inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the treatment of moderate to severe plaque psoriasis: A systematic review and Network meta-analysis of randomized controlled trials","volume":"2019","author":"Bai","year":"2019","journal-title":"J. Immunol. Res."},{"key":"B7","doi-asserted-by":"publisher","first-page":"497","DOI":"10.23736\/S2784-8671.22.07184-5","article-title":"Suicide risk and depression in patients with psoriasis","volume":"157","author":"Bardazzi","year":"2022","journal-title":"Ital. J. Dermatol. Venereol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1111\/bjd.18851","article-title":"A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial","volume":"182","author":"Blauvelt","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1001\/jamadermatol.2014.3593","article-title":"Economic burden of psoriasis in the United States: A systematic review","volume":"151","author":"Brezinski","year":"2015","journal-title":"JAMA Dermatol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1001\/jama.2022.21243","article-title":"Guidelines for reporting outcomes in trial protocols: The SPIRIT-Outcomes 2022 extension","volume":"328","author":"Butcher","year":"2022","journal-title":"JAMA"},{"key":"B11","first-page":"3176","article-title":"Simultaneous determination of 8 components of Guben Qushi Huayu Formula and prediction of its therapeutic target for psoriasis","volume":"46","author":"Chen","year":"2024","journal-title":"Chin. Tradit. Pat. Med."},{"volume-title":"Observation of Curative Effect of Guben Qushi Huayu Formula on Moderate Psoriasis Vulgaris and Analysis of Influencing Factors","year":"2022","author":"Chen","key":"B12"},{"key":"B13","doi-asserted-by":"publisher","first-page":"863","DOI":"10.19852\/j.cnki.jtcm.2020.05.017","article-title":"Effectiveness of Xiaoyin Jiedu granules in the treatment of psoriasis vulgaris in patients with blood-heat symptom patterns in terms of Traditional Chinese Medicine","volume":"40","author":"Chen","year":"2020","journal-title":"J. Tradit. Chin. Med."},{"key":"B14","first-page":"1033","article-title":"Chinese guidelines for the treatment of psoriasis biologics (2021)","volume":"54","year":"2021","journal-title":"Chin. J. Dermatology"},{"key":"B15","first-page":"573","article-title":"Chinese guideline of Diagnosis and treatment in Psoriasis (2023 edition)","volume":"56","year":"2023","journal-title":"Chin. J. Dermatology"},{"key":"B16","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1080\/14712598.2020.1729736","article-title":"Ixekizumab for the treatment of psoriasis: up-to-date","volume":"20","author":"Craig","year":"2020","journal-title":"Expert Opin. Biol. Ther."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.1080\/09546634.2021.1961998","article-title":"Efficacy, safety, and drug survival of IL-23, IL-17, and TNF-alpha inhibitors for psoriasis treatment: a retrospective study","volume":"33","author":"Dapavo","year":"2022","journal-title":"J. Dermatol. Treat."},{"key":"B18","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/bjd.17208","article-title":"Risk of first-time and recurrent depression in patients with psoriasis: a population-based cohort study","volume":"180","author":"Egeberg","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.jaad.2020.07.087","article-title":"Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures","volume":"84","author":"Elmets","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.jaad.2018.11.058","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities","volume":"80","author":"Elmets","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/S0140-6736(21)00184-7","article-title":"Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis","volume":"397","author":"Ghoreschi","year":"2021","journal-title":"Lancet"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1056\/NEJMc1610828","article-title":"Phase 3 trials of Ixekizumab in moderate-to-severe plaque psoriasis","volume":"375","author":"Gordon","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"B24","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1111\/bjd.13486","article-title":"Psoriasis treatment and management - a systematic review of full economic evaluations","volume":"172","author":"Hamilton","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1186\/s12955-014-0190-4","article-title":"Development and psychometric validation of the Chinese version of Skindex-29 and Skindex-16","volume":"12","author":"He","year":"2014","journal-title":"Health Qual. Life Outcomes"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1007\/s00403-022-02491-4","article-title":"Evaluation of Skindex-16 construct validity in routinely collected psoriasis data: a retrospective analysis of the relationship between overall physician global assessment scores and Skindex-16 and measure discordance","volume":"315","author":"Hopkins","year":"2023","journal-title":"Arch. Dermatol. Res."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2355261","DOI":"10.1080\/09546634.2024.2355261","article-title":"Adjunctive Chinese medicine therapy reduces relapse of psoriasis vulgaris after discontinuation of biologics: a prospective registry-based cohort study","volume":"35","author":"Huang","year":"2024","journal-title":"J. Dermatol. Treat."},{"key":"B28","doi-asserted-by":"publisher","first-page":"e3977","DOI":"10.1002\/cbf.3977","article-title":"Yinxieling decoction ameliorates psoriasis by regulating the differentiation and functions of Langerhans cells via the TGF-\u03b21\/PU.1\/IL-23 signal axis","volume":"42","author":"Li","year":"2024","journal-title":"Cell. Biochem. Funct."},{"key":"B29","first-page":"692","article-title":"Effect of Traditional Chinese Medicine plus narrow-band medium-wave ultraviolet B radiation on moderate-to-severe psoriasis vulgaris in a case series","volume":"39","author":"Li","year":"2019","journal-title":"J. Tradit. Chin. Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1148445","DOI":"10.3389\/fphar.2023.1148445","article-title":"Effect of Chinese herbal medicine injections for treatment of psoriasis vulgaris: a systematic review and meta-analysis","volume":"14","author":"Li","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1159\/000526086","article-title":"Effect of Traditional Chinese Medicine on Psoriasis vulgaris: A meta-analysis and systematic review","volume":"30","author":"Lu","year":"2023","journal-title":"Complement. Med. Res."},{"key":"B32","first-page":"756","article-title":"Correlation analysis of gene chip and miRNA chip of peripheral blood mononuclear cells of psoriasis vulgaris complicated by blood stasis in patients using Yinxieling","volume":"43","author":"Lu","year":"2021","journal-title":"Hebei J. Traditional Chin. Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/S0140-6736(19)31772-6","article-title":"Psoriasis biologics: a new era of choice","volume":"394","author":"Mahil","year":"2019","journal-title":"Lancet"},{"key":"B34","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s40257-022-00679-y","article-title":"Time to relapse after discontinuing systemic treatment for psoriasis: A systematic review","volume":"23","author":"Masson","year":"2022","journal-title":"Am. J. Clin. Dermatol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1136\/annrheumdis-2019-215386","article-title":"A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-na\u00efve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial","volume":"79","author":"Mease","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics","volume":"80","author":"Menter","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1111\/jdv.13803","article-title":"DLQI as a major criterion for introduction of systemic agents in patients with mild psoriasis","volume":"30","author":"Mermin","year":"2016","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1136\/ebnurs-2019-103076","article-title":"How to appraise mixed methods research","volume":"22","author":"Moorley","year":"2019","journal-title":"Evid. Based Nurs."},{"key":"B39","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1684\/ejd.2022.4245","article-title":"Global trends in the incidence of psoriasis from 1990 to 2019","volume":"32","author":"Mou","year":"2022","journal-title":"Eur. J. Dermatol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jaad.2015.04.011","article-title":"Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE)","volume":"73","author":"Mrowietz","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1111\/ddg.14508","article-title":"German S3-Guideline on the treatment of Psoriasis vulgaris, adapted from EuroGuiDerm - Part 1: Treatment goals and treatment recommendations","volume":"19","author":"Nast","year":"2021","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"B42","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1111\/jdv.16915","article-title":"EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 1: treatment and monitoring recommendations","volume":"34","author":"Nast","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s10488-010-0314-z","article-title":"Mixed method designs in implementation research","volume":"38","author":"Palinkas","year":"2011","journal-title":"Adm. Policy. Ment. Health"},{"key":"B44","doi-asserted-by":"publisher","first-page":"m1590","DOI":"10.1136\/bmj.m1590","article-title":"National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study","volume":"369","author":"Parisi","year":"2020","journal-title":"BMJ"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1080\/0142159X.2024.2373877","article-title":"Importance of mixed methods in medical education research","volume":"1","author":"Pineda-Canar","year":"2024","journal-title":"Med. Teach."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1111\/jdv.14642","article-title":"Depression and suicidality in psoriasis patients: emotional needs to discover","volume":"31","author":"Poot","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1111\/bjd.15666","article-title":"Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study","volume":"177","author":"Reich","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"24","DOI":"10.2174\/2589977513666210707114520","article-title":"IL-23\/Th17 Axis: A potential therapeutic target of psoriasis","volume":"14","author":"Sharma","year":"2022","journal-title":"Curr. Drug Res. Rev."},{"key":"B49","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.jclinepi.2011.07.011","article-title":"The size of a pilot study for a clinical trial should be calculated in relation to considerations of precision and efficiency","volume":"65","author":"Sim","year":"2012","journal-title":"J. Clin. Epidemiol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/S0140-6736(16)00047-7","article-title":"Ixekizumab for psoriasis","volume":"387","author":"Tsuda","year":"2016","journal-title":"Lancet"},{"key":"B51","doi-asserted-by":"publisher","first-page":"118166","DOI":"10.1016\/j.jep.2024.118166","article-title":"Chinese herbal medicine bath therapy for psoriasis vulgaris using topical calcipotriol as the comparator: A systematic review with meta-analysis and association rule analysis","volume":"330","author":"Wang","year":"2024","journal-title":"J. Ethnopharmacol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"155381","DOI":"10.1016\/j.phymed.2024.155381","article-title":"Adding Chinese herbal medicine bath therapy to conventional therapies for psoriasis vulgaris: A systematic review with meta-analysis of randomised controlled trials","volume":"128","author":"Wang","year":"2024","journal-title":"Phytomedicine"},{"key":"B53","doi-asserted-by":"publisher","first-page":"2998","DOI":"10.1097\/CM9.0000000000001232","article-title":"Time to relapse after treatment withdrawal for different biologics used to treat plaque psoriasis","volume":"133","author":"Wang","year":"2020","journal-title":"Chin. Med. J. Engl."},{"key":"B54","doi-asserted-by":"publisher","first-page":"652","DOI":"10.19852\/j.cnki.jtcm.20220602.002","article-title":"Mixed methods research in complementary and alternative medicine: a scoping review","volume":"42","author":"Wanqing","year":"2022","journal-title":"J. Tradit. Chin. Med."},{"key":"B55","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1111\/jdv.16964","article-title":"Time to relapse after tildrakizumab withdrawal in patients with moderate-to-severe psoriasis who were responders at week 28: post hoc analysis through 64 weeks from reSURFACE 1 trial","volume":"35","author":"Warren","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1136\/postgradmedj-2015-133419","article-title":"TNF-alpha in a molecularly targeted therapy of psoriasis and psoriatic arthritis","volume":"92","author":"Wcislo-Dziadecka","year":"2016","journal-title":"Postgrad. Med. J."},{"volume-title":"To Explore the Mechanism of Guben Qushi Huayu Fornula in Treating Psoriasis Based on Network Pharmacology and Metabolomics","year":"2021","author":"Xiang","key":"B57"},{"key":"B58","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1007\/s11655-022-3683-8","article-title":"Chinese Medicine as supporting therapy for Psoriasis: Past, present, and future","volume":"29","author":"Yang","year":"2023","journal-title":"Chin. J. Integr. Med."},{"key":"B59","first-page":"1048","article-title":"Meta-analysis of efficacy and safety of Yinxieling tablet and its optimized formula in the treatment of psoriasis vulgaris","volume":"32","author":"Yu","year":"2021","journal-title":"Traditional Chin. Drug Res. Clin. Pharmacol."},{"key":"B60","first-page":"63","article-title":"Effects of Guben Qushi Huayu formula on the Skin lesions and spleen water transport RelatedSubstances in a mouse Model of psoriasis relapse","volume":"44","author":"Zhang","year":"2024","journal-title":"Chin. J. Integr. Traditional West. Med."},{"key":"B61","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s11655-009-0145-5","article-title":"Effect of Chinese herbal medicine combined with acitretin capsule in treating psoriasis of blood-heat syndrome type","volume":"15","author":"Zhang","year":"2009","journal-title":"Chin. J. Integr. Med."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1551001\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T05:17:18Z","timestamp":1742534238000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1551001\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,21]]},"references-count":61,"alternative-id":["10.3389\/fphar.2025.1551001"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1551001","relation":{},"ISSN":["1663-9812"],"issn-type":[{"type":"electronic","value":"1663-9812"}],"subject":[],"published":{"date-parts":[[2025,3,21]]},"article-number":"1551001"}}